Discovering the causes of sarcoidosis, and ultimately a cure, can be uncovered through rigorous and collaborative scientific research.
Our initiatives and grants focus on collaborations which advance the understanding of sarcoidosis and address the causes of the disease, the suffering of patients, and the potential for a cure for sarcoidosis. FSR has provided annual Research Awards, Abstract Awards, and Research Support to select programs. Clinically applied research is critical to achieving our mission and our grants have been critical is supporting many studies. Collectively we have awarded and planned for $4 million in grants to support innovative research projects leading to additional millions of dollars in subsequent awards to our researchers.
Current funding opportunities include: There are no open funding opportunities at this time.
Our current and past grants include:
FSR Clinical Studies Network (2015-2020)
FSR launched our Clinical Studies Network – the world’s first clinical research network specific to sarcoidosis – in 2015 with 8 inaugural sites. This consortium brings together an international partnership of world-renowned medical institutes and researchers for unprecedented collaboration in studies and drug trials toward the treatment of sarcoidosis. In its first two years, the network has conducted two internal studies and multiple industry-initiated trials. The second grant period of the FSR-CSN opened in Fall 2017, with total investment of $1,280,000 since the CSN was formed.
Sarcoidosis Disease Model (2017-2020)
A major limiting factor in discovering new insights into the pathogenesis of sarcoidosis is the lack of a viable disease model. In a two-phase plan, FSR is funding early stage research in this area. The FSR Sarcoidosis Disease Model grant opportunity serves to ignite additional research and will help bridge funding for much-needed larger investments into the disease model space. The first grant amount totaled $750,000 for five awardees, and FSR recently awarded an additional $300,000 to bring the total investment in finding a sarcoidosis disease model up to $1,050,000 to date.
2019-2020 | Ohio State University – Elliott Crouser, MD, Landon Locke, PhD, Mark Julian, MS Yale School of Medicine – Erica Herzog, MD, PhD Medical University of Vienna – Thomas Weichhart, PhD |
2017-2019 | ·Medical University of Vienna – Thomas Weichhart, PhD ·Ohio State University – Elliott Crouser, MD, Larry Schlesinger, MD, Wolfgang Sadee, Dr.rer.nat, Peter White, PhD ·University of Freiburg – Peggy Engelhard, PhD, Gernot Zissel,PhD, Joachim Müller-Quernheim, MD, Marina A. Freudenberg, MD ·University of Hull, York Medical School – Simon Hart, MBChB, PhD ·Yale School of Medicine – Erica Herzog, MD, PhD |
Small Grants Program (2018-2020)
The Small Grant Program funds various field-initiated proposals in clinical and basic science settings. FSR focuses on well-defined projects that have the potential for impact on sarcoidosis research. FSR’s small grants are $25,000 per award.
2019 | 2019 Cycle 1 Award Winners: |
2018 | 2018 Cycle 1 Award Winner: Dr. Girish Bathla, University of Iowa: Vessel Wall imaging in Neurosarcoidosis: Underrecognized, Underdiagnosed and Undertreated. |
Fellowship Program (2018-2020)
Grants provided by FSR at a total of $1,000,000
As FSR works to further fill the pipeline of sarcoidosis experts, we are investing over $1,000,000 in four fellowships in sarcoidosis clinical and investigational research with our FSR Fellowship Program. In order to deepen the field of sarcoidosis specialist/experts, all are matched with top academic research/clinical care institutions and are in their first year of a fully-funded two-year grant period.
2018-2020 | Dr. Ozioma Chioma, Vanderbilt University Medical Center- Mentored by Dr. Wonder Drake Dr. Lori Garman, Oklahoma Medical Research Foundation- Mentored by Dr. Courtney Montgomery Dr. Changwan Ryu, Yale University- Mentored by Dr. Erica Herzog Dr. Bryan Young, Yale University- Mentored by Dr. Edward Miller |
Abstract Awards for Excellence in Sarcoidosis Research
Abstracts are brief summaries designed to succinctly communicate complex research projects. At scientific conferences, these are often presented in both text summary and poster form. FSR selects outstanding abstracts submitted to select medical and scientific conferences in order to provide an opportunity for young investigators to travel to meetings and present their data.
Year | Investigator, Institution & Project Summary |
2010 | Dia Beachboard, Vanderbilt University |
2009 | Ali A. Kanchwala, East Carolina University |
2008 | Takeshi Hattori, MD (First Department of Medicine, Hokkaido University) |
2007 | M. Gabrilovich, MD, PhD (Case Western Reserve) |
2006 | W.P. Drake, MD (Vanderbilt University) |
2005 | Andrew Shorr (Washington Hospital Center) |
ATS Research Grants
Through FSR’s partnership with ATS, we have funded $795,000 since 2005 in research grant funding, which has led to even more significant funding post-award. Below are the details of the funding:
2005-2020 | FSR has supported over $20,000 to support emerging researchers via the ATS Travel Grants to ensure up-and-coming investigators, many of whom submitted abstracts to ATS, can attend the annual conference to be included in the progression of education in lung disease. |
2011 | Nabeel Hamzeh, MD (National Jewish Health) |
2010 | Kyra Oswald-Richter (Vanderbilt University) |
2009 | Lobelia Samavati (Wayne State University) |
2008 | Elliott Crouser (Ohio State University) |
2008 | Edward Chen (Johns Hopkins University) |
2007 | Michael Falta (University of Colorado Health Sciences Center) |
2006 | Richard Silver (Case Western Reserve University)* |
2006 | Jan Wahlstrom (Karolinska University Hospital) |
2005 | Dan Culver (Cleveland Clinic)* |
Additional Research Support
National Disease Research Interchange (NDRI) Rare Disease Biospecimen Alliance (Ongoing)
This new alliance will facilitate tissue donation for research studies and accelerate the procurement and placement of sarcoidosis tissues with researchers.
Lecture Support for the 5th International World Association of Sarcoidosis and Other Granulomatous Disease (WASOG) Conference on Diffuse Lung Diseases (2009)
FSR provided financial support for this international conference focused on diffuse lung diseases.
Lecture Support for 2006 Aspen Lung Conference: Immunologic Diseases of the Lungs (2007)
FSR sponsored a lecture at this conference focused on the discovery of the cellular and molecular basis of immunologic lung diseases and the translation of these discoveries to novel treatment strategies.
WASOG Membership for Seven Young Investigators (2005)
FSR provided one year of WASOG membership with subscription to the scientific journal Sarcoidosis, Vasculitis & Diffuse Lung Diseases to seven investigators identified by abstract submission.
FSR Supports the University of Chicago (2004)
The University of Chicago Section of Pulmonary and Critical Care Medicine is
comprised of a world-class group of physicians and scientists who treat and
investigate the underlying causes of sarcoidosis and other similar diseases. As part of the Foundation’s mission to provide direct support to critically needed sarcoidosis research, a portion of proceeds from our Spring 2004 fundraiser were shared with the University of Chicago.
FSR Awards Grants through WASOG (2002-2017)
FSR awarded their first grants to two researchers selected at the 7th World Congress of The World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) Conference, held in Stockholm, Sweden. Helene Stridh, researcher at Karolinska Insitute, Stockholm, Sweden and Elske Hoitsma, researcher at University Hospital Maastricht, Holland, were chosen based upon questionnaires and abstracts they submitted to a peer review panel composed of some of the top sarcoidosis clinicians and researchers worldwide. Dr. Stridh’s work was focused on the study of the mechanisms of the overreaction of T-Lymphocytes in sarcoidosis patients and Dr. Hoitsma’s work was focused on small fiber neuropathy and autonomic dysfunction.
FSR has also supported WASOG and AASOG with sponsorship and research funding for its annual World Congress and U.S.-based meetings.
